Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Krystal Biotech stock (KRYS)

Buy Krystal Biotech stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Krystal Biotech is a biotechnology business based in the US. Krystal Biotech shares (KRYS) are listed on the NASDAQ and all prices are listed in US Dollars. Krystal Biotech employs 229 staff and has a trailing 12-month revenue of around $95.9 million.

Our top picks for where to buy Krystal Biotech stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Krystal Biotech stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – KRYS. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Krystal Biotech stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
★★★★★
Stocks, ETFs, Cryptocurrency
$0
$0
4.5%
N/A
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Moomoo
Finder Score: 4.3 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Public.com
Finder Score: 4.2 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
5.1%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Krystal Biotech stock price (NASDAQ: KRYS)

Use our graph to track the performance of KRYS stocks over time.

Krystal Biotech shares at a glance

Information last updated 2024-07-14.
Latest market close$203.66
52-week range$93.95 - $204.98
50-day moving average $171.32
200-day moving average $141.02
Wall St. target price$189.00
PE ratio 93.6083
Dividend yield N/A (0%)
Earnings per share (TTM) $2.17

Is it a good time to buy Krystal Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Krystal Biotech price performance over time

Historical closes compared with the close of $203.66 from 2024-07-19

1 week (2024-07-15) -2.03%
1 month (2024-06-21) 16.50%
3 months (2024-04-22) 29.51%
6 months (2024-01-22) 55.45%
1 year (2023-07-21) 69.28%
2 years (2022-07-22) 190.98%
3 years (2021-07-22) 227.06%
5 years (2019-07-22) 297.00%

Is Krystal Biotech stock undervalued or overvalued?

Valuing Krystal Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Krystal Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Krystal Biotech's P/E ratio

Krystal Biotech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 94x. In other words, Krystal Biotech shares trade at around 94x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Krystal Biotech financials

Revenue TTM $95.9 million
Operating margin TTM 12.85%
Gross profit TTM $0
Return on assets TTM -4.97%
Return on equity TTM 8.87%
Profit margin 59.57%
Book value $28.02
Market Capitalization $5.8 billion

TTM: trailing 12 months

Krystal Biotech share dividends

We're not expecting Krystal Biotech to pay a dividend over the next 12 months.

Krystal Biotech share price volatility

Over the last 12 months, Krystal Biotech's shares have ranged in value from as little as $93.95 up to $204.98. A popular way to gauge a stock's volatility is its "beta".

KRYS.US volatility(beta: 0.84)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Krystal Biotech's is 0.836. This would suggest that Krystal Biotech's shares are less volatile than average (for this exchange).

Krystal Biotech overview

Krystal Biotech, Inc. , a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. .

Frequently asked questions

What percentage of Krystal Biotech is owned by insiders or institutions?
Currently 12.67% of Krystal Biotech shares are held by insiders and 96.396% by institutions.
How many people work for Krystal Biotech?
Latest data suggests 229 work at Krystal Biotech.
When does the fiscal year end for Krystal Biotech?
Krystal Biotech's fiscal year ends in December.
Where is Krystal Biotech based?
Krystal Biotech's address is: 2100 Wharton Street, Pittsburgh, PA, United States, 15203
What is Krystal Biotech's ISIN number?
Krystal Biotech's international securities identification number is: US5011471027
What is Krystal Biotech's CUSIP number?
Krystal Biotech's Committee on Uniform Securities Identification Procedures number is: 501147102

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site